Arg-Gly-Asp-Ser
Arg-Gly-Asp-Ser structure
|
Common Name | Arg-Gly-Asp-Ser | ||
|---|---|---|---|---|
| CAS Number | 91037-65-9 | Molecular Weight | 433.41700 | |
| Density | 1.65g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C15H27N7O8 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of Arg-Gly-Asp-SerArg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9. |
This table lists Chinese names, IUPAC names and various aliases of this chemical substance.
| Name | RGDS peptide |
|---|---|
| Synonym | More Synonyms |
This table contains bioactivity, target information and biological‑assay experimental data of this compound.
| Description | Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9. |
|---|---|
| Related Catalog | |
| In Vitro | The Arg-Gly-Asp-Ser-modified surface causes up-regulation of αvβ3 integrin. Attachment to the Arg-Gly-Asp-Ser-treated membrane completely abolishes apoptosis induced by staurosporine, the Ca2+·Pi ion pair, and sodium nitroprusside. Arg-Gly-Asp-Ser-dependent resistance to apoptosis is eliminated, when the activity of the phosphatidylinositol 3-kinase pathway is inhibited[1]. Arg-Gly-Asp-Ser interacts with survivin, as well as with procaspase-3, -8 and -9. Arg-Gly-Asp-Ser-peptide binding to survivin is found to be specific, at high affinity (Kd 27.5 μM) and locates at the survivin C-terminus. Arg-Gly-Asp-Ser-survivin interaction appears to play a key role, since Arg-Gly-Asp-Ser lost its anti-mitogenic effect in survivin-deprived cells with a specific siRNA[4]. |
| In Vivo | Arg-Gly-Asp-Ser (2.5 or 5 mg/kg, 1 h before LPS) significantly inhibits LPS-induced MMP-9 activity in BAL fluid 4 h post-LPS. Arg-Gly-Asp-Ser (1, 2.5 or 5 mg/kg, i.p.) administers 1 h before LPS inhibited LPS-induced increases in TNF-α and MIP-2 levels in BAL fluid at 4 h post-LPS[2]. Arg-Gly-Asp-Ser peptide significantly reduces tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 production, and decreases myeloperoxidase (MPO) and NF-κB activity[3]. |
| Cell Assay | Cell death is measured using the MTT analysis. This assay is based on the ability of mitochondrial dehydrogenases to oxidize thiazolyl blue (MTT), a tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide), to an insoluble blue formazan product. The cells are incubated with the MTT reagent (120 μg/mL) at 37°C for 2 h. After the supernatant is removed, 400 μL of 0.04mol/LHCl in isopropanol is added to each well, and the optical density of the solution is read at 590 nm in an enzyme-linked immunosorbent assay plate reader. As the generation of the blue product is proportional to the dehydrogenase activity, a decrease in the absorbance at 590 nm provides a direct measurement of the number of viable cells. To determine the contribution of the PI3K pathway to inhibition of apoptosis, some cell populations are pretreated with 50 μM LY294002, a PI3K inhibitor. Following this pretreatment, cell death is determined as described above. |
| Animal Admin | Mice pharyngeal aspiration is performed as described. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with Arg-Gly-Asp-Ser or RGES peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered Arg-Gly-Asp-Ser or RGES peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS |
| References |
This table shows physicochemical parameters including melting point, boiling point, density, solubility and optical rotation. Missing data is marked as N/A.
| Density | 1.65g/cm3 |
|---|---|
| Molecular Formula | C15H27N7O8 |
| Molecular Weight | 433.41700 |
| Exact Mass | 433.19200 |
| PSA | 270.05000 |
| Index of Refraction | 1.659 |
| InChIKey | NNRFRJQMBSBXGO-CIUDSAMLSA-N |
| SMILES | NC(N)=NCCCC(N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)O |
| Storage condition | -20°C |
This table provides MSDS information including hazard classification, first‑aid, fire‑fighting, spill handling, operation and storage instructions.
This table covers safety warnings, protective measures, incompatible substances and disposal guidelines for this compound.
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xn |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
This table presents publicly reported synthetic routes, reaction conditions, reactants and product information of the compound.
This table lists upstream starting materials and downstream derivative products related to this chemical.
| Precursor 7 | |
|---|---|
| DownStream 0 | |
CAS#:199166-39-7
CAS#:246516-47-2
CAS#:63024-02-2
CAS#:143783-29-3
CAS#:13836-37-8
CAS#:105916-77-6
CAS#:788804-09-1This table lists relevant public references with title, journal and publication metadata for this compound.
|
Oligodendrocytes Are Targets of HIV-1 Tat: NMDA and AMPA Receptor-Mediated Effects on Survival and Development.
J. Neurosci. 35 , 11384-98, (2015) Myelin pallor in HIV(+) individuals can occur very early during the disease process. While myelin damage might partly originate from HIV-induced vascular changes, the timing suggests that myelin and/o... |
|
|
Emulating native periosteum cell population and subsequent paracrine factor production to promote tissue engineered periosteum-mediated allograft healing.
Biomaterials 52 , 426-40, (2015) Emulating autograft healing within the context of decellularized bone allografts has immediate clinical applications in the treatment of critical-sized bone defects. The periosteum, a thin, osteogenic... |
|
|
Cross-talk between transforming growth factor-β₁ and muscarinic M₂ receptors augments airway smooth muscle proliferation.
Am. J. Respir. Cell. Mol. Biol. 49(1) , 18-27, (2013) Transforming growth factor-β₁ (TGF-β₁) is a central mediator in tissue remodeling processes, including fibrosis and airway smooth muscle (ASM) hyperplasia, as observed in asthma. The mechanisms underl... |
This table contains target information, in‑vitro & in‑vivo assay data for this compound.
This table collects all English aliases, systematic names and CAS‑related synonyms of the compound.
| L-ARG-GLY-ASP-SER |
| RGDS |
| fibronectin active fragment |
| L-Arg-Gly-L-Asp-L-Ser-OH |
| RGDS/ARG-GLY-ASP-SER |
| Arg-Gly-Asp-Ser |
| FIBRONECTIN INHIBITOR |
| MFCD00076452 |
| RGDS 1/2ACOH 2H2O |
| H-ARG-GLY-ASP-SER-OH |
| Arg-Gly-Asp-Ser-OH |
| R-G-D-S |
This section contains frequently‑asked‑questions about this compound, including basic parameters, properties, storage conditions and corresponding answers.
| Q: What is the molecular weight of RGDS peptide? |
| A: Molecular weight of RGDS peptide is 433.41700. |
| Q: What are the uses of RGDS peptide? |
| A: Main uses of RGDS peptide: Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9. |
| Q: What is the SMILES notation of RGDS peptide? |
| A: SMILES notation of RGDS peptide is NC(N)=NCCCC(N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)O. |
| Q: What are the upstream materials of RGDS peptide? |
| A: Related upstream materials(CAS) of RGDS peptide: 199166-39-7;246516-47-2;63024-02-2;143783-29-3;13836-37-8;105916-77-6;788804-09-1. |
| Q: What English synonyms does RGDS peptide have? |
| A: English synonyms of RGDS peptide: L-ARG-GLY-ASP-SER, RGDS, fibronectin active fragment, L-Arg-Gly-L-Asp-L-Ser-OH, RGDS/ARG-GLY-ASP-SER, Arg-Gly-Asp-Ser, FIBRONECTIN INHIBITOR, MFCD00076452, RGDS 1/2ACOH 2H2O, H-ARG-GLY-ASP-SER-OH, Arg-Gly-Asp-Ser-OH, R-G-D-S. |
| Q: What are the storage conditions for RGDS peptide? |
| A: Storage conditions for RGDS peptide: -20°C. |
| Q: What is the InChIKey of RGDS peptide? |
| A: InChIKey of RGDS peptide is NNRFRJQMBSBXGO-CIUDSAMLSA-N. |
| Q: What is the molecular formula of RGDS peptide? |
| A: Molecular formula of RGDS peptide is C15H27N7O8. |
| Q: What is the CAS number of RGDS peptide? |
| A: CAS number of RGDS peptide is 91037-65-9. |
| Q: What is the English name of RGDS peptide? |
| A: The English name of RGDS peptide is RGDS peptide. |
This table lists manufacturers and suppliers of this compound, including vendor names and product supply reference information.
| Shanghai Nianxing Industrial Co., Ltd |